20/20 Biolabs, Inc. revenue by segment AIDX

20/20 Biolabs, Inc. splits its revenue into 3 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was One Test at $695,947, 95% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Revenue
—
1
0
One Test
—
1
share 95.3%
0
share 87.8%
Bio Check
—
0
share 4.7%
0
share 6.1%
CLI Ax
—
—
0
share 6.1%
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Services-Testing Laboratories (SIC 8734)
Listed as
AIDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Rockville, MD
SEC filer status
, Emerging growth company
SEC CIK
1139685
Former names
20/20 GeneSystems, Inc. (until Feb 26, 2025); 20/20 GENE SYSTEMS INC (until Apr 28, 2004)

Other Services-Testing Laboratories companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.